Table 3.

Associations between participant characteristics and COVID-19 symptoms in solid carcinoma patients.

Variable	COVID-19 infection		General symptom		Respiratory symptom		Digestive tract symptom		Fever (≥38°C)		Muscular soreness
	N (%)	p	N (%)	p	N (%)	p	N (%)	p	N (%)	p	N (%)	p
Sex
Male	112 (81.2)	0.303	20 (95.2)	0.953	8 (38.1)	0.107	2 (9.5)	1.000	15 (78.9)	0.967	9 (42.9)	0.535
Female	122 (76.3)		30 (90.9)		20 (60.6)		3 (9.1)		23 (74.2)		17 (51.5)
Age, years
18-59	89 (76.1)	0.407	23 (95.8)	0.771	15 (62.5)	0.161	2 (8.3)	1.000	19 (82.6)	0.313	12 (50.0)	0.808
≥60	145 (80.1)		27 (90.0)		13 (43.3)		3 (10.0)		19 (70.4)		14 (46.7)
BMI (kg/m2)
<25.0	59 (89.4)	0.831	41 (95.3)	0.181*	24 (55.8)	0.249	5 (11.6)	0.546	33 (82.5)	0.082	21 (48.8)	0.841
≥25.0	16 (84.2)		9 (81.3)		4 (36.4)		0 (0.0)		5 (50.0)		5 (45.5)
Vaccine (s) administered
Yes	159 (89.8)	<0.001	48 (92.3)	1.000*	27 (51.9)	1.000*	5 (9.6)	1.000*	36 (75.0)	1.000*	25 (48.1)	1.000*
No	75 (62.0)		2 (100.0)		1 (50.0)		0 (0.0)		2 (100.0)		1 (50.0)
Type of carcinoma
Lung carcinoma	15 (68.2)	0.211	3 (75.0)	0.634*	2 (50.0)	0.518*	0 (0.0)	0.758*	1 (25.0)	0.136*	1 (25.0)	0.297*
Digestive carcinoma	66 (80.5)		9 (100.0)		3 (33.3)		2 (22.2)		7 (77.8)		5 (55.6)
Liver carcinoma	17 (85.0)		1 (100.0)		1 (100.0)		0 (0.0)		1 (100.0)		1 (100.0)
Breast carcinoma	34 (68.0)		12 (92.3)		9 (69.2)		2 (15.4)		8 (66.7)		8 (61.5)
Thyroid carcinoma	17 (81.0)		5 (100.0)		3 (60.0)		0 (0.0)		3 (75.0)		4 (80.0)
Prostate carcinoma	29 (90.6)		6 (85.7)		2 (28.6)		0 (0.0)		4 (80.0)		2 (28.6)
Other carcinomas	55 (78.6)		14 (93.3)		8 (53.3)		1 (6.7)		14 (93.3)		5 (33.3)

Data are presented as number of participants (%). Statistical analyses were conducted using the Chi-squared test and Fisher’s exact test*.